SNOT-22 (Sinonasal Outcome Test)
Patient-reported outcome measure for chronic rhinosinusitis: 22 items scored 0–5, total 0–110 (Hopkins 2009). Enter the total from the completed SNOT-22 form; severity bands per Toma & Hopkins 2016.
Score interpretation
SNOT-22 under 8.
→ Reassurance; continue current medical management; review annually
Mild sinonasal symptom burden (Toma & Hopkins 2016).
→ Optimise medical therapy: intranasal steroids, saline irrigation, allergy management; ENT review if plateau
Moderate sinonasal symptom burden.
→ Optimise medical therapy (intranasal steroids, saline irrigation, allergy management); ENT review if not improving
Severe sinonasal symptom burden.
→ ENT referral; CT sinuses; consider functional endoscopic sinus surgery (FESS); assess for polyps and asthma
Interpretation bands for the SNOT-22. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Mupirocin 2% Ointment · Topical antibiotic (pseudomonic acid)
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Chlorhexidine with neomycin · Topical nasal antiseptic/antibiotic
- Glucagon · Hypoglycaemia Antidote / Endocrine Agent
- Tetracosactide · Synthetic ACTH (short Synacthen test)
- Budesonide Nasal Spray · Intranasal corticosteroid
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.
